Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

C. Eng; T.W. Kim; J. Bendell; G. Argilés; N.C. Tebbutt; M. Di Bartolomeo; A. Falcone; M. Fakih; M. Kozloff; N.H. Segal; A. Sobrero; Y. Yan; I. Chang; A. Uyei; L. Roberts; F. Ciardiello; J.B. Ahn; J. Asselah; S. Badarinath; S. Baijal; S. Begbie; S. Berry; J.L. Canon; R.G. Carbone; A. Cervantes; Y.J. Cha; K. Chang; A. Chaudhry; E. Chmielowska; S.H. Cho; D. Chu; F. Couture; J. Cultrera; D. Cunningham; E. Van Cutsem; P.J. Cuyle; J. Davies; S. Dowden; M. Dvorkin; V. Ganju; R.V. Garcia; R. Kerr; T.Y. Kim; K. King; J. Kortmansky; K.O. Lam; J. Lee; A.S. Lee; B. Lesperance; E. Maiello

doi:10.1016/S1470-2045(19)30027-0

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

C. Eng, T.W. Kim, J. Bendell, G. Argilés, N.C. Tebbutt, M. Di Bartolomeo, A. Falcone, M. Fakih, M. Kozloff, N.H. Segal, A. Sobrero, Y. Yan, I. Chang, A. Uyei, L. Roberts, F. Ciardiello, J.B. Ahn, J. Asselah, S. Badarinath, S. BaijalS. Begbie, S. Berry, J.L. Canon, R.G. Carbone, A. Cervantes, Y.J. Cha, K. Chang, A. Chaudhry, E. Chmielowska, S.H. Cho, D. Chu, F. Couture, J. Cultrera, D. Cunningham, E. Van Cutsem, P.J. Cuyle, J. Davies, S. Dowden, M. Dvorkin, V. Ganju, R.V. Garcia, R. Kerr, T.Y. Kim, K. King, J. Kortmansky, K.O. Lam, J. Lee, A.S. Lee, B. Lesperance, E. Maiello

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	849-861
Number of pages	13
Journal	The Lancet Oncology
Volume	20
Issue number	6
DOIs	https://doi.org/10.1016/S1470-2045(19)30027-0
Publication status	Published - 2019

Access to Document

10.1016/S1470-2045(19)30027-0

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066145160&doi=10.1016%2fS1470-2045%2819%2930027-0&partnerID=40&md5=1035e5f8777d2dc731de8d4a6c7ba5fa

Cite this

Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., Sobrero, A., Yan, Y., Chang, I., Uyei, A., Roberts, L., Ciardiello, F., Ahn, J. B., Asselah, J., Badarinath, S., ... Maiello, E. (2019). Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet Oncology, 20(6), 849-861. https://doi.org/10.1016/S1470-2045(19)30027-0

Eng, C, Kim, TW, Bendell, J, Argilés, G, Tebbutt, NC, Di Bartolomeo, M , Falcone, A, Fakih, M, Kozloff, M, Segal, NH, Sobrero, A, Yan, Y, Chang, I, Uyei, A, Roberts, L, Ciardiello, F, Ahn, JB, Asselah, J, Badarinath, S, Baijal, S, Begbie, S, Berry, S, Canon, JL, Carbone, RG, Cervantes, A, Cha, YJ, Chang, K, Chaudhry, A, Chmielowska, E, Cho, SH, Chu, D, Couture, F, Cultrera, J, Cunningham, D, Van Cutsem, E, Cuyle, PJ, Davies, J, Dowden, S, Dvorkin, M, Ganju, V, Garcia, RV, Kerr, R, Kim, TY, King, K, Kortmansky, J, Lam, KO, Lee, J, Lee, AS, Lesperance, B & Maiello, E 2019, 'Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial', The Lancet Oncology, vol. 20, no. 6, pp. 849-861. https://doi.org/10.1016/S1470-2045(19)30027-0

@article{5c578ee6c7db4d178f020cb0a9b41525,

title = "Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial",

author = "C. Eng and T.W. Kim and J. Bendell and G. Argil{\'e}s and N.C. Tebbutt and {Di Bartolomeo}, M. and A. Falcone and M. Fakih and M. Kozloff and N.H. Segal and A. Sobrero and Y. Yan and I. Chang and A. Uyei and L. Roberts and F. Ciardiello and J.B. Ahn and J. Asselah and S. Badarinath and S. Baijal and S. Begbie and S. Berry and J.L. Canon and R.G. Carbone and A. Cervantes and Y.J. Cha and K. Chang and A. Chaudhry and E. Chmielowska and S.H. Cho and D. Chu and F. Couture and J. Cultrera and D. Cunningham and {Van Cutsem}, E. and P.J. Cuyle and J. Davies and S. Dowden and M. Dvorkin and V. Ganju and R.V. Garcia and R. Kerr and T.Y. Kim and K. King and J. Kortmansky and K.O. Lam and J. Lee and A.S. Lee and B. Lesperance and E. Maiello",

note = "Cited By :25 Export Date: 13 February 2020",

year = "2019",

doi = "10.1016/S1470-2045(19)30027-0",

language = "English",

volume = "20",

pages = "849--861",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "6",

}

TY - JOUR

T1 - Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

AU - Eng, C.

AU - Kim, T.W.

AU - Bendell, J.

AU - Argilés, G.

AU - Tebbutt, N.C.

AU - Di Bartolomeo, M.

AU - Falcone, A.

AU - Fakih, M.

AU - Kozloff, M.

AU - Segal, N.H.

AU - Sobrero, A.

AU - Yan, Y.

AU - Chang, I.

AU - Uyei, A.

AU - Roberts, L.

AU - Ciardiello, F.

AU - Ahn, J.B.

AU - Asselah, J.

AU - Badarinath, S.

AU - Baijal, S.

AU - Begbie, S.

AU - Berry, S.

AU - Canon, J.L.

AU - Carbone, R.G.

AU - Cervantes, A.

AU - Cha, Y.J.

AU - Chang, K.

AU - Chaudhry, A.

AU - Chmielowska, E.

AU - Cho, S.H.

AU - Chu, D.

AU - Couture, F.

AU - Cultrera, J.

AU - Cunningham, D.

AU - Van Cutsem, E.

AU - Cuyle, P.J.

AU - Davies, J.

AU - Dowden, S.

AU - Dvorkin, M.

AU - Ganju, V.

AU - Garcia, R.V.

AU - Kerr, R.

AU - Kim, T.Y.

AU - King, K.

AU - Kortmansky, J.

AU - Lam, K.O.

AU - Lee, J.

AU - Lee, A.S.

AU - Lesperance, B.

AU - Maiello, E.

N1 - Cited By :25 Export Date: 13 February 2020

PY - 2019

Y1 - 2019

U2 - 10.1016/S1470-2045(19)30027-0

DO - 10.1016/S1470-2045(19)30027-0

M3 - Article

VL - 20

SP - 849

EP - 861

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 6

ER -